Relapsed Burkitt’s lymphoma is nearly always fatal. Three patients had a complete metabolic response with the combination of the bispecific antibody glofitamab and the antibody–drug conjugate polatuzumab vedotin. Full correspondence: nej.md/4lS7kfe
#MedSky #Hematology
#MedSky #Hematology
May 4, 2025 at 4:03 PM
Relapsed Burkitt’s lymphoma is nearly always fatal. Three patients had a complete metabolic response with the combination of the bispecific antibody glofitamab and the antibody–drug conjugate polatuzumab vedotin. Full correspondence: nej.md/4lS7kfe
#MedSky #Hematology
#MedSky #Hematology
This morning at #ASH24 we spoke to Julio Chavez MD on advances in #lymphoma care including...
🩸Mosunetuzumab SC + polatuzumab improves outcomes over rituximab + polatuzumab in R/R LBCL
🩸Golcadomide ± rituximab shows durable efficacy in R/R follicular & diffuse
@ash-hematology.bsky.social #HemOnc
🩸Mosunetuzumab SC + polatuzumab improves outcomes over rituximab + polatuzumab in R/R LBCL
🩸Golcadomide ± rituximab shows durable efficacy in R/R follicular & diffuse
@ash-hematology.bsky.social #HemOnc
December 8, 2024 at 6:53 PM
This morning at #ASH24 we spoke to Julio Chavez MD on advances in #lymphoma care including...
🩸Mosunetuzumab SC + polatuzumab improves outcomes over rituximab + polatuzumab in R/R LBCL
🩸Golcadomide ± rituximab shows durable efficacy in R/R follicular & diffuse
@ash-hematology.bsky.social #HemOnc
🩸Mosunetuzumab SC + polatuzumab improves outcomes over rituximab + polatuzumab in R/R LBCL
🩸Golcadomide ± rituximab shows durable efficacy in R/R follicular & diffuse
@ash-hematology.bsky.social #HemOnc
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Adding polatuzumab vedotin to treatment with R-GemOx can improve survival outcomes in patients with R/R diffuse large B-cell #lymphoma. Presented at @hemasphere-journal.bsky.social #EHA2025.
bit.ly/4lLWJSn
#DLBCL #lymphsm
bit.ly/4lLWJSn
#DLBCL #lymphsm
Polatuzumab Vedotin Improves PFS, OS in Rel/Ref DLBCL - Hematology Advisor
Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.
bit.ly
July 15, 2025 at 3:34 PM
Adding polatuzumab vedotin to treatment with R-GemOx can improve survival outcomes in patients with R/R diffuse large B-cell #lymphoma. Presented at @hemasphere-journal.bsky.social #EHA2025.
bit.ly/4lLWJSn
#DLBCL #lymphsm
bit.ly/4lLWJSn
#DLBCL #lymphsm
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology
www.onclive.com/view/mosunet...
www.onclive.com/view/mosunet...
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL
Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.
www.onclive.com
September 6, 2025 at 5:11 PM
Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology
www.onclive.com/view/mosunet...
www.onclive.com/view/mosunet...
At #ASH24, join Gilles Salles for a presentation on the five-year analysis of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone for patients with diffuse large B-cell #lymphoma.
9:30 a.m. PST @mskcancercenter.bsky.social
https://buff.ly/4it7tnB
9:30 a.m. PST @mskcancercenter.bsky.social
https://buff.ly/4it7tnB
December 8, 2024 at 3:00 PM
At #ASH24, join Gilles Salles for a presentation on the five-year analysis of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone for patients with diffuse large B-cell #lymphoma.
9:30 a.m. PST @mskcancercenter.bsky.social
https://buff.ly/4it7tnB
9:30 a.m. PST @mskcancercenter.bsky.social
https://buff.ly/4it7tnB
👑 RCHOP remains king/queen in limited stage DLBCL.
✅ PET adapted therapy - best for assessing risk groups for recurrence.
✅ Polatuzumab - better for Non GCB subtype and elderly subgroup - at the cost of increased neuropathy
☢️RT if decreased chemo tolerance ⬇️
#lymphoma #oncsky #heme #cancers
✅ PET adapted therapy - best for assessing risk groups for recurrence.
✅ Polatuzumab - better for Non GCB subtype and elderly subgroup - at the cost of increased neuropathy
☢️RT if decreased chemo tolerance ⬇️
#lymphoma #oncsky #heme #cancers
December 1, 2024 at 1:10 AM
Hans IHC discrimination of Cell-of-Origin Subtype is a valid method for predicting Polatuzumab response in DLBCL aacrjournals.org/clincancerre...
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma
AbstractPurpose:. Polatuzumab vedotin (polatuzumab) was approved for up-front treatment of diffuse large B-cell lymphoma in combination with chemoimmunotherapy (Pola-R-CHP) based on the POLARIX trial....
aacrjournals.org
November 30, 2025 at 4:32 PM
Hans IHC discrimination of Cell-of-Origin Subtype is a valid method for predicting Polatuzumab response in DLBCL aacrjournals.org/clincancerre...
In the phase III POLARGO trial, @drmatasar.bsky.social reported that adding polatuzumab vedotin to R-GemOx reduced mortality by ~40% in relapsed/refractory DLBCL.
📊 270 patients
⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60)
🔗 ascopost.com/issues/july-...
#DLBCL #PolatuzumabVedotin
📊 270 patients
⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60)
🔗 ascopost.com/issues/july-...
#DLBCL #PolatuzumabVedotin
July 29, 2025 at 7:48 PM
In the phase III POLARGO trial, @drmatasar.bsky.social reported that adding polatuzumab vedotin to R-GemOx reduced mortality by ~40% in relapsed/refractory DLBCL.
📊 270 patients
⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60)
🔗 ascopost.com/issues/july-...
#DLBCL #PolatuzumabVedotin
📊 270 patients
⏱️ Median OS: 19.5 vs 12.5 months (HR 0.60)
🔗 ascopost.com/issues/july-...
#DLBCL #PolatuzumabVedotin
A Match Made in Heaven? How the Addition of Polatuzumab Vedotin to Bispecific Antibodies Has Improved Outcomes in Second-Line Diffuse Large B-Cell Lymphoma url: ashpublications.org/thehematolog...
A Match Made in Heaven? How the Addition of Polatuzumab Vedotin to Bispecific Antibodies Has Improved Outcomes in Second-Line Diffuse Large B-Cell Lymphoma
Budde LE, Zhang H, Kim WS, . Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of
ashpublications.org
March 23, 2026 at 8:29 PM
A Match Made in Heaven? How the Addition of Polatuzumab Vedotin to Bispecific Antibodies Has Improved Outcomes in Second-Line Diffuse Large B-Cell Lymphoma url: ashpublications.org/thehematolog...
Glofitamab and Polatuzumab Vedotin Deliver High Efficacy in Relapsed B-Cell Lymphoma Despite Prior Treatments.
by Hutchings M, Sureda A (...) Gritti G et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00992
by Hutchings M, Sureda A (...) Gritti G et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00992
October 29, 2025 at 2:17 AM
Glofitamab and Polatuzumab Vedotin Deliver High Efficacy in Relapsed B-Cell Lymphoma Despite Prior Treatments.
by Hutchings M, Sureda A (...) Gritti G et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00992
by Hutchings M, Sureda A (...) Gritti G et 17 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-25-00992
More reasons not to use RGemOx if you have access to Mosun, Glofit and/or pola:
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
ASCO Publications
ascopubs.org
October 3, 2025 at 11:55 AM
More reasons not to use RGemOx if you have access to Mosun, Glofit and/or pola:
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
now out in JCO nice work Dr Budde, @lymphomadoc.bsky.social et al
Mosunetuzumab + polatuzumab vedotin in transplant-ineligible R/R large B-cell lymphoma: results of the phase 3 SUNMO trial ascopubs.org/doi/10.1200/...
POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalk youtu.be/dQgSOcmHvDA?... via @YouTube
In this video, Dr. Stanchina discusses the POLARIX Trial and the addition of Polatuzumab to frontline chemotherapy for Diffuse Large B-Cell Lymphoma (DLBCL).
In this video, Dr. Stanchina discusses the POLARIX Trial and the addition of Polatuzumab to frontline chemotherapy for Diffuse Large B-Cell Lymphoma (DLBCL).
POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalk
YouTube video by GRACE - Global Resource for Advancing Cancer Education
youtu.be
November 7, 2024 at 2:33 PM
POLARIX Trial and Polatuzumab in Frontline Chemotherapy for DLBCL - 2024 Blood Cancer OncTalk youtu.be/dQgSOcmHvDA?... via @YouTube
In this video, Dr. Stanchina discusses the POLARIX Trial and the addition of Polatuzumab to frontline chemotherapy for Diffuse Large B-Cell Lymphoma (DLBCL).
In this video, Dr. Stanchina discusses the POLARIX Trial and the addition of Polatuzumab to frontline chemotherapy for Diffuse Large B-Cell Lymphoma (DLBCL).
Our letter by Nicolas Munz on in vitro lymphoma models for polatuzumab vedotin is now online in the British Journal of Haematology. Thanks to everybody at @iorbellinzona.bsky.social @usi.ch @snsf.ch
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
Polatuzumab vedotin and CD79B: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma
Click on the article title to read more.
onlinelibrary.wiley.com
October 8, 2025 at 4:40 AM
Our letter by Nicolas Munz on in vitro lymphoma models for polatuzumab vedotin is now online in the British Journal of Haematology. Thanks to everybody at @iorbellinzona.bsky.social @usi.ch @snsf.ch
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
scientiasalut.gencat.cat
March 26, 2026 at 10:41 AM
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Dr. Marc Hoffman shares data on golcadamide plus R-CHP and polatuzumab vedotin for therapy-naive DLBCL. #ASCO26 @kucancercenter.bsky.social,
Read more here: sohoinsider.com/lymphoma/gol...
Read more here: sohoinsider.com/lymphoma/gol...
June 24, 2026 at 12:03 PM
Dr. Marc Hoffman shares data on golcadamide plus R-CHP and polatuzumab vedotin for therapy-naive DLBCL. #ASCO26 @kucancercenter.bsky.social,
Read more here: sohoinsider.com/lymphoma/gol...
Read more here: sohoinsider.com/lymphoma/gol...
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL #lymphoma after BTK inhibitor therapy: a phase 2 study
pubmed.ncbi.nlm.nih.gov/42013019/
AI abstract summary
and How it works
pubmed.ncbi.nlm.nih.gov/42013019/
AI abstract summary
and How it works
August 10, 2026 at 5:17 PM
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL #lymphoma after BTK inhibitor therapy: a phase 2 study
pubmed.ncbi.nlm.nih.gov/42013019/
AI abstract summary
and How it works
pubmed.ncbi.nlm.nih.gov/42013019/
AI abstract summary
and How it works
Striking results in untreated indolent B-cell NHL: a chemo-free approach hit a 100% response rate and 86% complete response rate in a phase 2 trial.
Read more: sohoinsider.com/news/mosunet...
Read more: sohoinsider.com/news/mosunet...
Mosunetuzumab plus response-adapted polatuzumab vedotin, obinutuzumab shows promise as chemotherapy-free option for indolent B-cell non-Hodgkin lymphoma
Mosunetuzumab, a bispecific antibody against CD3 and CD20, followed by response-adapted polatuzumab vedotin and obinutuzumab provided encouraging complete response (CR) rates and progression-free…
sohoinsider.com
August 29, 2026 at 3:26 PM
Striking results in untreated indolent B-cell NHL: a chemo-free approach hit a 100% response rate and 86% complete response rate in a phase 2 trial.
Read more: sohoinsider.com/news/mosunet...
Read more: sohoinsider.com/news/mosunet...
Ready for a Dose? Which treats neonatal respiratory distress syndrome?
A. Polatuzumab
B. Poractant
C. Posaconazole
D. Polyethylene glycol
See next
#PhunQuiz #TwitteRx #XRx #MedX #NAPLEX #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmacyStudents #Rx #PharmacyTechnicians #PTCB
A. Polatuzumab
B. Poractant
C. Posaconazole
D. Polyethylene glycol
See next
#PhunQuiz #TwitteRx #XRx #MedX #NAPLEX #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmacyStudents #Rx #PharmacyTechnicians #PTCB
November 20, 2024 at 3:19 PM
Ready for a Dose? Which treats neonatal respiratory distress syndrome?
A. Polatuzumab
B. Poractant
C. Posaconazole
D. Polyethylene glycol
See next
#PhunQuiz #TwitteRx #XRx #MedX #NAPLEX #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmacyStudents #Rx #PharmacyTechnicians #PTCB
A. Polatuzumab
B. Poractant
C. Posaconazole
D. Polyethylene glycol
See next
#PhunQuiz #TwitteRx #XRx #MedX #NAPLEX #Medicines #Pharmacy #Pharmacology #NCLEX #FOAMed #Pharmacists #PharmacyStudents #Rx #PharmacyTechnicians #PTCB
Promising results with mosunetuzumab + polatuzumab in R/R mantle cell lymphoma:
• Phase 2, n=42
• Median age: 68 years
• Median prior lines: 3 (prior BTKi 100%; prior CAR T-cell 26%)
• ≥3 high-risk features: 71%
• ORR: 88%
• CR: 79%
• CRS: 43%, all grade 1–2
ashpublications.org/blood/articl...
• Phase 2, n=42
• Median age: 68 years
• Median prior lines: 3 (prior BTKi 100%; prior CAR T-cell 26%)
• ≥3 high-risk features: 71%
• ORR: 88%
• CR: 79%
• CRS: 43%, all grade 1–2
ashpublications.org/blood/articl...
ashpublications.org
August 19, 2026 at 9:51 AM
Promising results with mosunetuzumab + polatuzumab in R/R mantle cell lymphoma:
• Phase 2, n=42
• Median age: 68 years
• Median prior lines: 3 (prior BTKi 100%; prior CAR T-cell 26%)
• ≥3 high-risk features: 71%
• ORR: 88%
• CR: 79%
• CRS: 43%, all grade 1–2
ashpublications.org/blood/articl...
• Phase 2, n=42
• Median age: 68 years
• Median prior lines: 3 (prior BTKi 100%; prior CAR T-cell 26%)
• ≥3 high-risk features: 71%
• ORR: 88%
• CR: 79%
• CRS: 43%, all grade 1–2
ashpublications.org/blood/articl...
Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL @ash-hematology.bsky.social #ASH24 #lymsm #oncology www.onclive.com/view/glofita...
Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL
Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.
www.onclive.com
December 10, 2024 at 6:26 PM
Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL @ash-hematology.bsky.social #ASH24 #lymsm #oncology www.onclive.com/view/glofita...
PML 與哪些血液用藥有關
JC virus 在嚴重細胞免疫低下時再活化，破壞少突膠質細胞造成多灶性去髓鞘。
相關藥物：rituximab、fludarabine、brentuximab vedotin、polatuzumab vedotin —— 四者都有報告。
高危三族群記 HAM：HIV、血液惡性腫瘤、使用 natalizumab 的多發性硬化症。
#血液專科
https://hema-2026.hsiehting.com/q/110-081
JC virus 在嚴重細胞免疫低下時再活化，破壞少突膠質細胞造成多灶性去髓鞘。
相關藥物：rituximab、fludarabine、brentuximab vedotin、polatuzumab vedotin —— 四者都有報告。
高危三族群記 HAM：HIV、血液惡性腫瘤、使用 natalizumab 的多發性硬化症。
#血液專科
https://hema-2026.hsiehting.com/q/110-081
August 4, 2026 at 7:42 AM
PML 與哪些血液用藥有關
JC virus 在嚴重細胞免疫低下時再活化，破壞少突膠質細胞造成多灶性去髓鞘。
相關藥物：rituximab、fludarabine、brentuximab vedotin、polatuzumab vedotin —— 四者都有報告。
高危三族群記 HAM：HIV、血液惡性腫瘤、使用 natalizumab 的多發性硬化症。
#血液專科
https://hema-2026.hsiehting.com/q/110-081
JC virus 在嚴重細胞免疫低下時再活化，破壞少突膠質細胞造成多灶性去髓鞘。
相關藥物：rituximab、fludarabine、brentuximab vedotin、polatuzumab vedotin —— 四者都有報告。
高危三族群記 HAM：HIV、血液惡性腫瘤、使用 natalizumab 的多發性硬化症。
#血液專科
https://hema-2026.hsiehting.com/q/110-081
Great activity in heavily-pretx & very high-risk MCL. Severe infections are common theme with BsAb. #lymsm
ashpublications.org/blood/articl...
2/2
ashpublications.org/blood/articl...
2/2
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
Key PointsFixed-duration Mosun-Pola is effective for R/R MCL, including high-risk features: objective response rate, 88%; complete response rate, 79%.With
ashpublications.org
August 10, 2026 at 2:43 PM
Great activity in heavily-pretx & very high-risk MCL. Severe infections are common theme with BsAb. #lymsm
ashpublications.org/blood/articl...
2/2
ashpublications.org/blood/articl...
2/2
Patients with #DLBCL being treated with a regimen of polatuzumab vedotin and rituximab, ifosfamide, carboplatin, and etoposide (PolaR-ICE) showed a 2-year PFS rate of 49.9% and a 2-year OS rate of 75%.
Read here: https://bit.ly/4vNJxC9
#HemOnc
Read here: https://bit.ly/4vNJxC9
#HemOnc
PolaR-ICE Regimen Shows Promise Among Patients With Relapsed or Refractory DLBCL
Researchers determined PolaR-ICE may be safe and effective in patients with relapsed or refractory DLBCL in the second-line setting.
bit.ly
April 23, 2026 at 8:18 PM
Patients with #DLBCL being treated with a regimen of polatuzumab vedotin and rituximab, ifosfamide, carboplatin, and etoposide (PolaR-ICE) showed a 2-year PFS rate of 49.9% and a 2-year OS rate of 75%.
Read here: https://bit.ly/4vNJxC9
#HemOnc
Read here: https://bit.ly/4vNJxC9
#HemOnc
Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL
@ash.hematology.org #ASH24 #lymsm
www.onclive.com/view/pola-r-...
@ash.hematology.org #ASH24 #lymsm
www.onclive.com/view/pola-r-...
Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL
Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.
www.onclive.com
February 7, 2025 at 9:21 PM
Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL
@ash.hematology.org #ASH24 #lymsm
www.onclive.com/view/pola-r-...
@ash.hematology.org #ASH24 #lymsm
www.onclive.com/view/pola-r-...